×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CRSP – crispr therapeutics ag - common shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CRSP
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/18
10:41 am
crsp
Should You Buy Shares of CRISPR Therapeutics in February? [Yahoo! Finance]
Low
Report
Should You Buy Shares of CRISPR Therapeutics in February? [Yahoo! Finance]
2/17
11:55 am
crsp
CRISPR Therapeutics Q4: The Elite Time To Buy Is In 2027 [Seeking Alpha]
Low
Report
CRISPR Therapeutics Q4: The Elite Time To Buy Is In 2027 [Seeking Alpha]
2/17
09:09 am
crsp
CRISPR Therapeutics (NASDAQ:CRSP) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
CRISPR Therapeutics (NASDAQ:CRSP) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.
2/16
08:05 am
crsp
CRISPR Therapeutics (NASDAQ:CRSP) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
CRISPR Therapeutics (NASDAQ:CRSP) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
2/15
02:13 am
crsp
Is CRISPR Therapeutics' (CRSP) Casgevy Momentum Enough to Offset Steep 2025 Revenue Declines? [Yahoo! Finance]
Low
Report
Is CRISPR Therapeutics' (CRSP) Casgevy Momentum Enough to Offset Steep 2025 Revenue Declines? [Yahoo! Finance]
2/14
09:06 am
crsp
Crispr Therapeutics price target raised to $82 from $80 at Needham [Yahoo! Finance]
Low
Report
Crispr Therapeutics price target raised to $82 from $80 at Needham [Yahoo! Finance]
2/14
09:06 am
crsp
Crispr Therapeutics price target raised to $74 from $62 at Evercore ISI [Yahoo! Finance]
Low
Report
Crispr Therapeutics price target raised to $74 from $62 at Evercore ISI [Yahoo! Finance]
2/14
08:00 am
crsp
CRISPR Therapeutics (NASDAQ:CRSP) was given a new $76.00 price target on by analysts at Chardan Capital.
Low
Report
CRISPR Therapeutics (NASDAQ:CRSP) was given a new $76.00 price target on by analysts at Chardan Capital.
Date
Time
Symbol
Company Name
Action
%Chg
2/12/2026
04:30 pm
CRSP
crispr therapeutics ag - common shares
MISS
Report
10.1%
crispr therapeutics ag - common shares
11/10/2025
08:00 am
CRSP
crispr therapeutics ag - common shares
BEAT
Report
-6.2%
crispr therapeutics ag - common shares
8/4/2025
04:15 pm
CRSP
crispr therapeutics ag - common shares
MISS
Report
-7.1%
crispr therapeutics ag - common shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/17
12:06 pm
crsp
Form SCHEDULE 13G/A CRISPR Therapeutics AG Filed by: ORBIS INVESTMENT MANAGEMENT LTD
Low
Report
Form SCHEDULE 13G/A CRISPR Therapeutics AG Filed by: ORBIS INVESTMENT MANAGEMENT LTD
2/12
04:59 pm
crsp
Form 10-K CRISPR Therapeutics AG For: Dec 31
Medium
Report
Form 10-K CRISPR Therapeutics AG For: Dec 31
2/12
04:35 pm
crsp
Form 8-K CRISPR Therapeutics AG For: Feb 12
Medium
Report
Form 8-K CRISPR Therapeutics AG For: Feb 12
2/5
02:05 pm
crsp
Form SCHEDULE 13G/A CRISPR Therapeutics AG Filed by: Capital International Investors
Low
Report
Form SCHEDULE 13G/A CRISPR Therapeutics AG Filed by: Capital International Investors
1/27
05:35 pm
crsp
Form 4 CRISPR Therapeutics AG For: Apr 03 Filed by: Patel Naimish
Low
Report
Form 4 CRISPR Therapeutics AG For: Apr 03 Filed by: Patel Naimish
1/26
05:35 pm
crsp
Form 4 CRISPR Therapeutics AG For: Jan 22 Filed by: Prasad Raju
Low
Report
Form 4 CRISPR Therapeutics AG For: Jan 22 Filed by: Prasad Raju
1/22
05:55 pm
crsp
Form 4 CRISPR Therapeutics AG For: Jan 20 Filed by: Kulkarni Samarth
Medium
Report
Form 4 CRISPR Therapeutics AG For: Jan 20 Filed by: Kulkarni Samarth
1/22
05:15 pm
crsp
Form 144 CRISPR Therapeutics AG Filed by: Kulkarni Samarth
Medium
Report
Form 144 CRISPR Therapeutics AG Filed by: Kulkarni Samarth
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/19
CRISPR Therapeutics down 4% premarket on initial CTX001 data [Seeking Alpha]
19.1%
2/28 Can CRISPR Therapeutics Double Your Money in 2020? [The Motley Fool] 13.1%
10/28 Q3/2019 9/30/2019 EPS 2.400 ZacksConsensus N/A ActVsEst N/A - N/A 12.5%
8/5 Form 4 CRISPR Therapeutics AG For: Aug 01 Filed by: Ho Tony W 7.5%
2/7 First CRISPR Gene Editing Trial in Cancer Patients Shows Promising Results [The Motley Fool] 6.8%
12/2 Form 4 CRISPR Therapeutics AG For: Dec 01 Filed by: Kulkarni Samarth 6.3%
11/22 Form 8-K CRISPR Therapeutics AG For: Nov 19 6.1%
10/30 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at TheStreet from a "d" rating to a "c" rating. 5.9%
6/6 Form 8-K CRISPR Therapeutics AG For: Jun 06 5.6%
4/24 Form DEF 14A CRISPR Therapeutics AG For: Jun 11 5.5%
2/28 Can CRISPR Therapeutics Double Your Money in 2020? [The Motley Fool] 13.1%
10/28 Q3/2019 9/30/2019 EPS 2.400 ZacksConsensus N/A ActVsEst N/A - N/A 12.5%
8/5 Form 4 CRISPR Therapeutics AG For: Aug 01 Filed by: Ho Tony W 7.5%
2/7 First CRISPR Gene Editing Trial in Cancer Patients Shows Promising Results [The Motley Fool] 6.8%
12/2 Form 4 CRISPR Therapeutics AG For: Dec 01 Filed by: Kulkarni Samarth 6.3%
11/22 Form 8-K CRISPR Therapeutics AG For: Nov 19 6.1%
10/30 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at TheStreet from a "d" rating to a "c" rating. 5.9%
6/6 Form 8-K CRISPR Therapeutics AG For: Jun 06 5.6%
4/24 Form DEF 14A CRISPR Therapeutics AG For: Jun 11 5.5%
TOP News Decliners
11/20
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
-10.6%
3/31 Form 8-K CRISPR Therapeutics AG For: Mar 31 -10.4%
8/3 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -10.2%
12/27 Form 8-K CRISPR Therapeutics AG For: Dec 27 -7.5%
12/6 Crispr Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Wells Fargo & Co. -7.1%
2/21 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -6.5%
10/1 CRISPR Therapeutics to Present at Upcoming Investor Conferences -6.3%
9/25 Is CRISPR Therapeutics a Buy? [The Motley Fool] -5.9%
2/13 Crispr Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $72.50 price target on the stock. -5.6%
6/19 Form 4 CRISPR Therapeutics AG For: Jun 17 Filed by: Kulkarni Samarth -5.6%
3/31 Form 8-K CRISPR Therapeutics AG For: Mar 31 -10.4%
8/3 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -10.2%
12/27 Form 8-K CRISPR Therapeutics AG For: Dec 27 -7.5%
12/6 Crispr Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Wells Fargo & Co. -7.1%
2/21 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -6.5%
10/1 CRISPR Therapeutics to Present at Upcoming Investor Conferences -6.3%
9/25 Is CRISPR Therapeutics a Buy? [The Motley Fool] -5.9%
2/13 Crispr Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $72.50 price target on the stock. -5.6%
6/19 Form 4 CRISPR Therapeutics AG For: Jun 17 Filed by: Kulkarni Samarth -5.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: